Lunai Bioworks Inc.
Lunai Bioworks Inc. (RENB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
renb · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Lunai Bioworks Inc. (RENB) measures how much investors pay for each dollar of the company's trailing earnings. RENB's current PE ratio of N/A is calculated by dividing its stock price of $1.42 by its TTM earnings per share of -$41.06.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lunai Bioworks Inc.You RENB | $33M | N/A | — | -$41.06 |
 Allakos Inc. ALLK | $30M | N/A | — | -$1.30 |
 Angion Biomedica Corp. ANGN | $30M | N/A | — | -$2.58 |
 Freeline Therapeutics Holdings plc FRLN | $28M | N/A | — | -$22.52 |
 Grace Therapeutics, Inc. GRCE | $37M | N/A | — | -$1.13 |
 Opus Genetics, Inc. IRD | $330M | N/A | — | -$0.08 |
 LianBio LIANY | $12M | 2.11x | — | $0.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | — | $-1.08 | — | |
2024-06-30 FY2024 | — | $-8.38 | — | |
2023-06-30 FY2023 | — | $-7.05 | — | |
2022-06-30 FY2022 | — | $-21.59 | — | |
2021-06-30 FY2021 | — | $-5.67 | — | |
2020-06-30 FY2020 | — | $-2.46 | — | |
2019-06-30 FY2019 | — | $-4.80 | — | |
2018-06-30 FY2018 | — | $-2.88 | — | |
2017-06-30 FY2017 | — | $-1.75 | — | |
2016-06-30 FY2016 | — | $-1.82 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lunai Bioworks Inc. (RENB) measures how much investors pay for each dollar of the company's trailing earnings. RENB's current PE ratio of N/A is calculated by dividing its stock price of $1.42 by its TTM earnings per share of -$41.06.
Frequently asked questions
RENB pe ratio · 6 questionsRENB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.42 and TTM EPS of -$41.06. Data sourced from Financial Modeling Prep via RENB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lunai Bioworks Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09